Priority 5 from the Autosomal Dominant Polycystic Kidney Disease Project
| UNCERTAINTY:What are the benefits and harms of drugs that can be used for the management of ADPKD including polycystic liver disease (PLD)? (Priority 5) | |
|---|---|
| Overall ranking | 5 |
| JLA question ID | 0103/5 |
| Explanatory note | Not available for this PSP |
| Evidence |
No evidence identified |
| Health Research Classification System category | Renal and urogenital |
| Extra information provided by this project | |
|---|---|
| Original uncertainty examples | Which sub-groups of people with ADPKD, including those at higher risk of clinical outcomes such as hypertension, are more likely to benefit from early intervention for example in relation to kidney volumes, range of kidney function and tendency to rapid disease progression? ~ What are the benefits and harms of somatostatin analogues for the management of ADPKD? |
| Submitted by | 2 x research recommendations |
| Project information | |
|---|---|
| Project unique ID | 0103 |
| Project name | Autosomal Dominant Polycystic Kidney Disease |
| Total number of uncertainties identified by this project. |
35 (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website) |
| Date of priority setting workshop | 15 December 2020 |